Rachel P. Rosovsky, M.D., M.P.H., is an assistant physician in the Department of Hematology/Oncology at Massachusetts General Hospital (MGH) in Boston and an instructor in medicine at Harvard Medical School (HMS). Dr. Rosovsky earned her undergraduate degree from the University of Pennsylvania, Doctor of Medicine degree from Harvard Medical School, and Master in Public Health degree from Harvard School of Public Health. She completed her residency at Brigham and Women’s Hospital and fellowship at the Dana-Farber Cancer Institute, both in Boston. She is board certified in hematology and medical oncology. She is an expert and leader in the field of venous thromboembolism (VTE), and her clinical and research interest and expertise revolve around the evaluation and treatment of patients with this condition. Dr. Rosovsky is on the Board of Directors of the National Pulmonary Embolism Response Team (PERT) Consortium, and she is Chair of the Consortium’s Education Committee.She recently helped establish a national educational series for PERT members to discuss the most up-to-date topics and controversies in the work up and treatment of VTE, as well as a monthly newsletter highlighting current evidence-based literature on VTE. Dr. Rosovsky also serves on the Executive Committee of the MGH PERT and is the creator and director of the MGH PERT multidisciplinary follow-up clinic, the goals of which are to improve the care of patients with pulmonary embolism as they transition from inpatient to outpatient setting, standardize follow-up protocols, increase patient satisfaction, and expand patient education. Dr. Rosovsky is actively engaged in the education of medical students, residents, and fellows. In addition to bedside teaching and supervision during outpatient clinics and inpatient rotations, she lectures at continuing medical education courses locally, nationally and internationally. Dr. Rosovsky is also actively involved in research, investigating the risks, diagnosis, and treatment of VTE and other benign hematological conditions. Past research includes an analysis of endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide and dexamethasone and a study of VTE risk in cancer patients with increased tissue factor particles who are treated with a low molecular weight heparin (LMWH). Currently, she is participating in an international study comparing a LMWH product with one of the new direct oral anticoagulants (DOACs) in cancer patients with acute VTE. She is also the co-principal investigator on a multicenter study investigating the safety and efficacy of treating low risk deep vein thrombosis and pulmonary embolism (PE) in an outpatient setting, and she is the national lead investigator for an evaluation of a DOAC for low risk PE patients. She is involved in creating a PERT registry and national database to assess current treatments and long-term outcomes in patients with VTE. Through lectures, research, and written works that include original articles, book chapters, and scholarly reviews, she seeks to improve the care of patients with VTE and advance the understanding and treatment of this medical condition.